Researchers from Australia have developed a groundbreaking mRNA vaccine against tuberculosis (TB), showing promising results in pre-clinical mouse trials. This innovative vaccine could outperform the ...

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials.

The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.

Coding assistance and completion tools saved developers around 4 million hours last year, the retailer said during an ...

CEOs emphasize the need to stay nimble and rethink supply chains as barriers to trade are erected in an increasingly ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

A beverage company thinks like a startup to maintain a closer connection with its customers. That’s the word from a recent episode of MIT’s and BCG’s Me, Myself, and AI, which featured Ronald den ...

A new mRNA vaccine against tuberculosis (TB) is showing favorable results in preclinical trials. With only one currently ...

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials ...

UroGen Pharma has opened another front in its attack on bladder cancer, paying IconOVir Bio $4 million in stock for an early-phase oncolytic virus that could work like a turbocharged Bacillus Calmette ...

ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...

ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an "alternative source ...